Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials

Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market